Role of PPAR Alpha in Controlling COX-2 and VEGF in Tumor Growth
Author Information
Author(s): Raquel Grau, Manuel D. Cacheiro-Llaguno, Cristina Fresno, Manuel Iñiguez, Miguel A. Iñiguez
Primary Institution: Centro de Biología Molecular “Severo Ochoa” UAM-CSIC, Universidad Autónoma de Madrid
Hypothesis
PPARα agonists may have therapeutic usefulness in antitumoral therapy by decreasing abnormal cell growth and reducing tumoral angiogenesis.
Conclusion
PPARα activation may inhibit tumor growth and angiogenesis by regulating the expression of COX-2 and VEGF.
Supporting Evidence
- PPARα agonists have been shown to inhibit COX-2 and VEGF expression.
- Activation of PPARα can lead to decreased tumor growth in various cancer types.
- PPARα ligands can suppress angiogenesis in tumor models.
- Evidence suggests that PPARα may have anti-inflammatory effects that contribute to its antitumoral properties.
Takeaway
This study suggests that a certain protein, PPARα, can help stop cancer from growing by blocking other proteins that make tumors grow.
Limitations
Many effects of PPARα ligands on tumor progression have been obtained in vitro and need further confirmation in clinical research.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website